

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Biomaterials for Total Joint Replacements

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1622868> since 2017-01-27T12:26:23Z

*Publisher:*

Springer-Verlag

*Published version:*

DOI:10.1007/978-1-84882-664-9





*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

## Metadata of the chapter that will be visualized online

Chapter Title	Biomaterials for Total Joint Replacements	
Copyright Year	2016	
Copyright Holder	Springer-Verlag London	
Corresponding Author	Family Name	<b>Brach del Prever</b>
	Particle	
	Given Name	<b>Elena M.</b>
	Suffix	
	Division	1st Orthopaedic Clinic University of Turin
	Organization/University	Centro Traumatologico Ortopedico
	City	Tu 
	Country	Italy
	Email	elena.brach@unito.it
Author	Family Name	<b>Costa</b>
	Particle	
	Given Name	<b>Luigi</b>
	Suffix	
	Division	Department of Molecular  Biotechnology and Health Sciences
	Organization/University	Molecular Imaging Center, University of Tur 
	City	Torino
	Country	Italy
Author	Family Name	<b>Piconi</b>
	Particle	
	Given Name	<b>Corrado</b>
	Suffix	
	Division	Department of Clinical Orthopedics
	Organization/University	Catholic University
	City	Tor 
	Country	Italy

---

Author	Family Name	<b>Baricco</b>
	Particle	
	Given Name	<b>Marcello</b>
	Suffix	
	Division	Laboratory of Metallurgy, Chemistry Department
	Organization/University	University of Turin
	City	Torino
	Country	Italy

---

Author	Family Name	<b>Massè</b>
	Particle	
	Given Name	<b>Alessandro</b>
	Suffix	
	Division	Department of Orthopaedics and Traumatology
	Organization/University	University of Turin
	City	Torino
	Country	Italy

---

Abstract	The role of the chemical-physical characteristics of the prosthetic biomaterials in the biomechanics of a total joint replacement is presented. The following main biomaterials are discussed: (1) the ultra high molecular weight polyethylene (UHMWPE): standard, cross linked, stabilized with vitamin E; (2) the polymethylmethacrylate (PMMA): standard cement, cements with low temperature polymerization, antibiotic-loaded cements; (3) the ceramic materials: oxide ceramics (over all Alumina-Zirconia Composites) as components of the artificial joint, and calcium phosphate ceramics as osteoconductive coatings on metal alloy components; (4) the metallic materials: stainless steel, alloys based on the Co-Cr system, Ti and its alloys. To know how the biomaterial modifies its mechanical properties in accordance with the manufacturing, sterilization, storage, handling, contact with- and reaction to the patient's tissues and fluids is fundamental for the researchers and the surgeons, allowing a successful implant.	
----------	--	--

---

Keywords (separated by " - ")	Total joint replacements - Joint replacement - Biomaterials for total joint replacement	
-------------------------------	---	--

---

# Biomaterials for Total Joint Replacements

5

Elena M. Brach del Prever, Luigi Costa,  
Corrado Piconi, Marcello Baricco,  
and Alessandro Massè

The European Society for Biomaterials defines a *biomaterial* “a material that interacts with the biological systems to evaluate, treat, reinforce or replace a tissue, organ or function of the organism” and the *biocompatibility* “the ability of a material to perform with an appropriate host response in a specific application” [1]. Recently, a new concept of biocompatibility was suggested in relation with the new technologies [2] and the fourth generation of biomaterials, the so-called smart or biomimetic materials [3]. Biocompatibility of a biomaterials is tested by in vitro screening, in vivo testing and clinical monitoring; each step evaluates the biological response in different conditions. In vivo, few

seconds after the implantation, the biomaterial is rapidly adsorbed by proteins, whose quantity and organisation depend on the characteristics of the biomaterial, such as chemical composition of the bulk and surface, surface geometry, chemical and physical properties and the properties of the proteins. The host cells contact the protein layer: in total joint replacements, bone cells growing on the prosthetic surface determine an *osseointegration*, fibrous cells as *fibrous fixation*. The production of wear and degradation particles, inevitable in all TJR, determines a biological response defined as *bioreactivity*; its major determinants are the particle size, concentration, surface chemical composition, surface energy, surface charge, surface roughness, particle shape and nature of adsorbed proteins; genetics might be influential in determining the biological response. The wear particles activate macrophages and initiate the inflammatory cascade resulting in bone loss and reduced bone production, prosthetic loosening and eventual TJR failure. New therapeutic strategies try to diminish particle-associated periprosthetic inflammation modifying the monocyte/macrophages migration and activation [4].

Some wear metal particles are able to accumulate in the periprosthetic tissues and enter in the bloodstream, and can be responsible for chromosomal aberrations and DNA damage, which may promote cancerogenesis. Genotoxicity or mutagenicity, and/or carcinogenicity were demonstrated in experimental studies with CoCr

E.M. Brach del Prever, MD (✉)  
1st Orthopaedic Clinic University of Turin,  
Centro Traumatologico Ortopedico, Turin, Italy  
e-mail: [elena.brach@unito.it](mailto:elena.brach@unito.it)

L. Costa, PhD  
Department of Molecular Biotechnology and Health  
Sciences, Molecular Imaging Center  
University of Turin, Torino, Italy

C. Piconi, MSc  
Department of Clinical Orthopedics,  
Catholic University, Turin, Italy

M. Baricco, PhD  
Laboratory of Metallurgy, Chemistry Department,  
University of Turin, Torino, Italy

A. Massè, MD  
Department of Orthopaedics and Traumatology,  
University of Turin, Torino, Italy

53 alloys, in accordance with epidemiological stud- 87  
 54 ies concerning the association of exposure to 88  
 55 chromate particles and the incidence of nasal and 89  
 56 lung cancer. Nickel is demonstrated to be geno- 90  
 57 toxic in vitro and carcinogenetic in vivo (lung and 91  
 58 ethmoidal bone). However, after an average of 13 92  
 59 years and up to 25 years of follow-up, no increased 93  
 60 cancer risk in patients with conventional total hip 94  
 61 replacements was demonstrated [5–7].

62 In some previously sensitised patients, abra- 95  
 63 sion and corrosion products could behave like 96  
 64 haptens, and the complex may stimulate memory- 97  
 65 lymphocytes initiating an inflammatory process. In 98  
 66 particular, metal particles can either act as haptens 99  
 67 bindings to protein carriers, or as adjuvants, forming 100  
 68 insoluble complexes with the antigens, initiating an 101  
 69 immune response. Hypersensitivity reactions have 102  
 70 been reported to be more frequent with stainless- 103  
 71 steel or cobalt alloy than with titanium alloy; hyper- 104  
 72 sensitivity to polymethylmethacrylate was found to 105  
 73 be 50 % in failed total hip implants. 106

74 The probability of developing a metal allergy 107  
 75 seems to be higher post-operatively and the risk 108  
 76 further increased when failed implants were 109  
 77 compared with stable TJRs [8]

the Ultra High Molecular Weight Polyethylene 87  
 (UHMWPE) is used because of its biocompatibility 88  
 and excellent mechanical properties. UHMWPE is 89  
 a high density PE (HDPE) with molecular mass 90  
 more than 2.000.000 amu; it is a semi-crystalline 91  
 polymer with a set of ordered regions (crystal- 92  
 line lamellae), where macromolecules are tightly 93  
 packed and the density is at its highest, embedded 94  
 in a disordered amorphous phase, where macro- 95  
 molecules are randomly arranged and orientated. 96


Table 5.1 shows the required characteristics of 97  
 hopaedic UHMWPE according to ASTM F648- 98  
 With an exception for the density (crystallinity 99  
 degree is expressed as the percentage by weight of 100  
 the crystalline regions present in the whole poly- 101  
 mer), there are virtually no superior limits for the 102  
 other characteristics. This means that UHMWPE 103  
 can have different starting characteristics, whether 104  
 chemical, physical or mechanical. It is worth men- 105  
 tioning that the determination of these characteris- 106  
 tics is carried out on the original material, before 107  
 processing and sterilisation [9–11]. 108

### Processing 109

The UHMWPE powder coming from the 110  
 Ziegler-Natta polymerisation plant is processed 111  
 by compression moulding and ram extrusion: 112  
 both techniques use high pressure and controlled 113  
 heating and cooling cycles, and do not signifi- 114  
 cantly modify chemical, physical and structural 115  
 characteristics of the starting polymer, with the 116  
 exception of crystallinity (which is normally 117  
 much higher in the pristine powder). Therefore 118  
 all prosthetic components, ready to be sterilised, 119  
 still retain all properties of the starting material. 120

## Ultra High Molecular Weight Polyethylene (UHMWPE)

80 A macromolecular chain of polyethylene (PE) 110  
 81 can be represented by the following formula: 111




82 There are many types of PE, all characterised 112  
 83 by the same structural unit, but with different 113  
 84 lengths, different space arrangements and different 114  
 85 chain imperfections. In total joint replacements, 115  
 86

t1.1 **Table 5.1** Requirements for UHMWPE fabricated forms, according to ASTM F 648

t1.2 Property (unit)	t1.3 Test method	Requirement for type I (GUR 1020)	Requirement for type II (GUR 1050)
t1.4 Density (g/cm <sup>3</sup> )	ASTM D-792	0.927–0.944	0.927–0.944
t1.5 Ash (mg/kg) (maximum)		125	125
t1.6 Tensile strength (MPa)	ASTM D 638		
t1.7 Ultimate (minimum)		40	40
t1.8 Yield (minimum)		21	19
t1.9 Elongation (%)	ASTM D 638	380	340
t1.10 Izod impact strength (kJ/m <sup>2</sup> ) (min)	ASTM F 648–10 Annex A1	126	73
t1.11 Charpy impact strength (kJ/m <sup>2</sup> ) (min)	ISO/CD 11542/2.3	180	90

**Fig. 5.1** The degradation of the UHMWPE induced by high energy radiation sterilization; in presence of oxygen, from the atmosphere, the process is called oxidation. Vitamin E is able to stabilize against oxidation



121 **Sterilisation**

122 The main sterilisation processes used nowadays  
 123 employ ethylene oxide (EtO), gas-plasma (GP)  
 124 and high-energy radiation (gamma radiation and  
 125 electron beam) [9–11].

126 EtO and GP are surface sterilization meth-  
 127 ods and do not significantly affect the physical,  
 128 chemical and mechanical properties of prosthetic  
 129 components. GP is based on the action of ionized  
 130 gas (i.e. hydrogen peroxide or peracetic acid).

131 Gamma radiations are emitted during decay of  
 132 a <sup>60</sup>Co unstable nucleus. The dose absorbed by  
 133 prosthetic components is about 25–30 kGy and  
 134 depends upon the geometry of the sample and its  
 135 position in relation with the source.

136 Electron beam is produced by thermally excit-  
 137 ing a tungsten filament; the emitted electrons are  
 138 accelerated by electric fields up to 10 MeV and  
 139 then conveyed onto the material to be sterilised.  
 140 The advantages of this method are the easy control  
 141 of the apparatus and the very short period of  
 142 treatment (seconds).

143 **Degradation and Oxidation**

144 Gamma radiation and electron beam have a mean  
 145 energy some orders of magnitude higher than that  
 146 of polymeric chemical bonds and therefore gener-  
 147 ate the scission of some chemical bonds of the  
 148 UHMWPE and formation of free radicals. If even  
 149 a single C-C bond of the UHMWPE chain is broken  
 150 and 2° CH<sub>2</sub>~ radicals are formed, the length

of the chain and consequently the molecular mass  
 decrease, with worsening of some chemical and  
 physical material characteristics. This process is  
 called **degradation** and in presence of oxygen,  
**oxidation**, which involves free radicals (Fig. 5.1).

The oxidative process depends on the radicals  
 (formed during sterilisation) and on the amount  
 of oxygen diffused into the PE components from  
 the atmosphere during processing, sterilisation if  
 conducted in presence of air and storage [12].

The distribution of oxidative products in the  
 prosthetic component depends from the follow-  
 ing variables: rate at which radiations is supplied,  
 temperature of the sterilisation chamber, amount  
 of oxygen present in the polymer when irradiated  
 and diffused afterwards. Both in new and  
 retrieved component, a *crown effect* or *white band*  
 was the macroscopic evidence of this oxidation,  
 responsible for many severe failures (delamina-  
 tion and fracture) during service *in vivo* in years  
 ‘90’. Unfortunately, the first dramatic failures of  
 UHMWPE components in the mid 1980s were  
 attributed to inadequate mechanical properties of  
 the UHMWPE, despite the evidence that these  
 properties were much better than those required  
 by ASTM F648.

**Packaging**

An adequate packaging of the components is  
 mandatory to assure the correct atmosphere in  
 accordance with the chosen sterilization process;  
 the packaging could be critical when high energy

182 radiation in vacuum or inert gases to reduce oxi-  
183 dation is used. Currently employed packaging  
184 can be included in three categories [13]:

- 185 – Gas-permeable packaging, adequate for EtO  
186 and GP sterilization: a polyethylene tere-  
187 phthalate (PET) blister with a Tyvek® cover;
- 188 – Polymer barrier packaging: multi-layer plastic  
189 bags with gas-barrier properties with limited  
190 but measurable permeability to oxygen;
- 191 – Aluminium barrier packaging: virtually  
192 impermeable to gases.

193 Ultimately, a complete absence of oxidation is  
194 obtained only by gas-sterilisation.

## 195 Debris and Diffusion

196 Polyethylene debris are particles loss due to fric-  
197 tion, caused by the reciprocal movement of the  
198 loaded articular surfaces: for equal mechanical  
199 stress, material and interface, abrasion is func-  
200 tion of time. Whereas dramatic failures due to  
201 anomalous wear of heavily oxidised polyethyl-  
202 ene have become quite uncommon nowadays,  
203 the production of abraded particles remains a  
204 problem in young patients whose life expectancy  
205 and quality of life are very high. The debris initi-  
206 ate an inflammatory reaction, the formation of a  
207 loosening membrane and a secondary osteolysis.  
208 The junctional tissue depends from number, size  
209 and chemical structures of UHMWPE debris.  
210 While pointing out that this topic is in continu-  
211 ous development, it is important to realise that  
212 the debris is not just simple UHMWPE particles,  
213 but biologically active particles whose surface  
214 interact with the human tissues according with  
215 their macro and micromorphology, contact area,  
216 molecules adsorpted on their surface, superficial  
217 hydrophilic and hydrophobic character, release  
218 of free radicals and time [9–11].

219 A process of adsorption and deep diffusion  
220 into the UHMWPE prosthetic components of  
221 organic molecules present in the synovial liquid,  
222 such as cholesterol, ester of cholesterol, squalene,  
223  $\beta$ -carotene, takes place in vivo. This diffusion  
224 explains the yellowish colour in some retrieved  
225 components [14].

## Crosslinked UHMWPE

226

To increase the abrasion resistance, crosslinked  
UHMWPE (X-PE) appeared on the market in the  
late 1990s [9–11, 15]. Crosslinking of a polymer  
is the linking of two or more molecular chains  
by means of chemical covalent bonds: macro  
radical species, formed by treatment with high  
energy, react with vinyl double bonds, linking the  
polymer chains with a C-C stable chemical bond  
and giving Y-crosslink. The X-PE can be repre-  
sented as one long, branched molecule with infi-  
nite molecular mass and consequent better wear  
resistance properties than standard UHMWPE,  
but also with some lower mechanical properties,  
owing to chemical and physical modifications  
induced by irradiation and heat treatment.

Commercially available X-PEs are obtained  
by different crosslinking processes, mainly based  
on gamma radiation or electron beam at doses  
ranging from 60 to 100 kGy at room temperature  
or in the molten state, depending on the manu-  
facturer; the residual radicals are eliminated by  
thermal treatment, sometime at temperature  
below the melting point of the polymer (typically  
at 130 °C) (annealing). The final sterilization is  
obtained by EtO or gas-plasma or, in few cases,  
by gamma radiation in low oxygen environment  
[12].

Due to different crosslinking processes, the  
commercial X-PEs can be very different with  
variable properties, while standard UHMWPE  
has and maintain its properties if processed and  
sterilised in adequate ways.

Even if dramatic oxidation levels are not  
observed in newly produced UHMWPE compo-  
nents, it must be kept in mind that also very low  
oxidation levels can lead to significant variations  
in the mechanical properties of the polymer.

## Vitamin E Stabilised UHMWPE

264

Vitamin E or, better, its synthetic derivative, alfa-  
tocopherol, is employed to stabilize UHMWPE  
against oxidation (ASTM F2695-12). As already  
pointed out, PE is easily subject to oxidation,  
which strongly compromises their mechani-  
cal properties. The oxidation is basically due to

271 the reaction between macroradicals and oxygen  
272 diffused into the polymer from the surround-  
273 ing atmosphere; Vitamin E decreases the macro  
274 alkyl radicals available to react with the oxygen  
275 and thus to a significant slowdown of the oxi-  
276 dative cascade [9–11, 15–17]. Unfortunately, a  
277 decreased number of available alkyl radicals is  
278 also responsible for a lower efficiency of cross-  
279 linking at the same radiation dose, but a correct  
280 vitamin E concentration and radiation dose deter-  
281 mine an oxidatively stable UHMWPE, without  
282 the need of a further thermal treatment, with  
283 enough crosslink density and consequent resis-  
284 tance to abrasion.

---

### 285 **Polymethylmethacrylate,** 286 **the Orthopaedic Cement**

287 Orthopaedic cement is basically poly(methyl  
288 methacrylate) (PMMA) obtained by polymeris-  
289 ing the methyl methacrylate monomer (MMA)  
290 [18, 19]. Usually it is supplied in two separate  
291 packages: a brown coloured vial (in order to  
292 avoid any negative influence of the light on the  
293 monomer) containing about 20 ml of transparent  
294 liquid, and one package or two containing 40 g  
295 of powder. The liquid contains: MMA, usually  
296 N,N dimethyl-p-toluidine (DMPT) to accelerate  
297 the polymerisation process in presence of radi-  
298 cals, and traces of hydroquinone to avoid prema-  
299 ture polymerisation of the monomer. The powder  
300 is formed by pre-synthesised PMMA (at times  
301 polymethylmethacrylate-styrene as copolymers  
302 are used), dibenzoyl peroxide (DBP) and barium  
303 sulphate (or zirconium dioxide), the latter may  
304 be supplied in a separate package. PMMA is  
305 in the shape of spherical particles having a vari-  
306 able diameter between 30 and 250  $\mu\text{m}$ ; the size  
307 of the particles determines the viscosity of the  
308 cement. When the contents of the two packages  
309 are mixed, DBP initiates the radical process of  
310 polymerisation through polymerisation accelera-  
311 tor and the effect of polymerisation heat. Barium  
312 sulphate makes the cement radio-opaque.

313 Cements produced by different industrial com-  
314 panies have different chemical-physical charac-  
315 teristics and mechanical properties due various  
316 components and their relative concentrations.

Bone cement preparation is characterised by 317  
three phases: the wetting phase corresponds to 318  
mixing the solid part with the liquid, the setting 319  
phase (divided into ‘dough time’ and ‘work- 320  
ing time’) corresponds to the initial polymeri- 321  
sation process (about 5 % of total), the curing 322  
phase corresponds to the final hardening phase 323  
and completion of the polymerisation process. 324  
During mixing, benzoyl peroxide, present on 325  
the surface of the PMMA powder, and DMPT 326  
present in the liquid, interact and the polymeri- 327  
sation process starts, mainly on the surface of 328  
the pre-synthesised poly(methyl methacrylate). 329  
Working time starts when a “dough” is obtained 330  
which no longer sticks to gloves and tempera- 331  
ture increase of the cement is minimal, corre- 332  
sponding to minimal transformation of MMA to 333  
PMMA. The final polymerisation phase is char- 334  
acterised by the rapid increase of polymerisa- 335  
tion rate and temperature. The time required for the 336  
various phases depend mainly on the tempera- 337  
ture in the operating theatre: a 10  $^{\circ}\text{C}$  increase 338  
causes polymerisation to start twice as quickly, 339  
cutting mixing times by half. After polymeriza- 340  
tion, less than 5 % of MMA remains free and this 341  
percentage may slowly spread into the body. The 342  
MMA polymerization reaction is exothermic; the 343  
high temperature favours DBP decomposition 344  
leading to an increase in radical formation and 345  
consequently an increase in polymerization pro- 346  
cess. Therefore, polymerization speed is initially 347  
minimal and gradually increases. Where process- 348  
ing carried out in adiabatic conditions, the bone 349  
cement temperature would reach 160  $^{\circ}\text{C}$ . The 350  
actual temperature reached by the cement dur- 351  
ing the surgery depends on the balance between 352  
quantity and speed with which the heat is pro- 353  
duced, and how easily the heat is dispersed from 354  
the surface into surrounding tissues. At the inter- 355  
face with spongy bone, due to vascularisation 356  
and the trabecular shape of the bone itself, tem- 357  
peratures of 60  $^{\circ}\text{C}$  can be reached, while in the 358  
centre of the mass of cement the temperature is 359  
higher than 100  $^{\circ}\text{C}$ . Schematically cement pro- 360  
duces heat in function of the used amount, and 361  
the temperature at the interface increases with the 362  
higher quantity of cement. Based on this assump- 363  
tion, an adequate surgical technique can lower 364  
the temperature at the interface by using both 365



366 an adequate and not too thick layer of cement,  
 367 and washing liquids in the final polymerization  
 368 phase. Some cements are declared as “low tem-  
 369 perature polymerization”. They are characterised  
 370 by a lower ratio monomer MMA/polymer that  
 371 proportionally lowers the heat developed during  
 372 transformation of monomer into polymer. High  
 373 temperature is sought when the cement is used  
 374 as adjuvant in bone tumours to ensure “sterilisa-  
 375 tion” of a bone surface from which the tumour  
 376 has been removed; therefore in oncological sur-  
 377 gery, standard PMMA is useful.

378 During polymerization reaction, a theoretical  
 379 volumetric shrinking of the PMMA takes place  
 380 proportional to the amount of MMA used; in the  
 381 orthopaedic cement, the volumetric shrinking is  
 382 7 % of the initial volume. Another characteristic  
 383 of cement is the porosity due to CO<sub>2</sub> formed dur-  
 384 ing decomposition of the initiator, MMA mono-  
 385 mer evaporation, air-bubble formed during hand  
 386 preparation of the mixture, and the expansion  
 387 due to temperature increase during polymerisa-  
 388 tion. In actual orthopaedic cements, the vacuum  
 389 technique preparation decreases air-bubble for-  
 390 mation; other factors cannot be eliminated.

391 Antibiotic-loaded cements are used in order to  
 392 obtain a greater quantity of local antibiotic and  
 393 to reduce the systemic quantity, thereby decreas-  
 394 ing general toxicity; they are whether industrially  
 395 packaged or prepared in the operating theatre  
 396 according to the antibiogramme [20]. The state  
 397 of the art on how the antibiotic manages to act  
 398 is the following: the antibiotic, when soluble in  
 399 water, dissolves from the surface of PMMA into  
 400 the tissues; antibiotic molecules of notable size  
 401 are physically blocked inside the bone cement  
 402 and, therefore, cannot spread from inside the  
 403 cement to the surface. The dissolution process  
 404 depends on the type of antibiotic, on the charac-  
 405 teristic of the surface of the cement and on the  
 406 way the cement itself is prepared. When the anti-  
 407 biotic is added to the cement during preparation  
 408 of the cement itself, that is in the operating room,  
 409 only a small part of the antibiotic molecules are  
 410 casually on the surface of the cement and will be  
 411 able to dissolve. This process explains why the  
 412 actual antibiotic-loaded cements have a limited  
 413 antiseptical action.

## Ceramic Biomaterials 414

415 Ceramics are solid materials, which have as  
 416 their essential component inorganic non-metallic  
 417 materials. In joint replacements oxide ceramics  
 418 are used as components of the artificial joint (ball  
 419 heads and inserts in hip replacements, femo-  
 420 ral component in knee replacements, glenoid in  
 421 shoulder replacements), while calcium phosphate  
 422 ceramics (CPCs) are used as osteoconductive  
 423 coatings on metal alloy components.

## Oxide Ceramics 424

425 Two ceramic oxides are used in joint replace-  
 426 ments: alumina and zirconia. Both are ionic sol-  
 427 ids, the high energy of the chemical bond giving  
 428 them a high resistance to the corrosion, hardness,  
 429 stiffness. The chemical stability of these oxides  
 430 is the root of the excellent biological safety of  
 431 their wear debris, a behaviour relevant for their  
 432 intended use in arthroprostheses' bearings [21].  
 433 So far (end 2014) more than 80 % of Total Hip  
 434 Replacements (THR) in Italy, France, Germany  
 435 and Austria are making use of ceramic ball  
 436 heads, as well as in Japan and Korea, while in  
 437 the USA ceramic ball heads are used in about  
 438 20 % of THR only. The market leader CeramTec  
 439 GmbH (Plochingen, Germany) declared to have  
 440 sold by 2014 ten million of BIOLOX® ceramic  
 441 bearing components. The behaviour of selected  
 442 oxide ceramics is shown in Table 5.2.

## Alumina 443

444 The development of alumina (aluminium oxide –  
 445 Al<sub>2</sub>O<sub>3</sub>) as a biomaterial began in the mid-60s, the  
 446 behaviour of alumina components (say total hip  
 447 replacement – THR ball heads) were improved  
 448 continuously over more than 40 years of clinical  
 449 use, making alumina one of the better char-  
 450 acterised biomaterials [22]. The material used in  
 451 biomedical application is α-alumina, known as  
 452 *corundum*, one of the most stable oxides, unaf-  
 453 fected by corrosion (e.g. absence of ion release  
 454 from bulk materials and from wear debris) in  
 455 the most adverse conditions. The biocompat-  
 456 ibility of alumina is a well-established property.

t2.1 **Table 5.2** Indicative values of selected properties of selected oxide bioceramics

t2.2	Properties (unit)	Unit	BIOLOX® <i>forte</i>	Prozyr®	BIOLOX® <i>delta</i>
t2.3	Usual name		Alumina	Zirconia Y-TZP	Alumina Matrix Composite (AMC)
t2.4					
t2.5	Chemical composition	wt %	>99.8 Alpha-Alumina	ZrO <sub>2</sub> +5,1 % Y <sub>2</sub> O <sub>3</sub>	Al <sub>2</sub> O <sub>3</sub> : 74 Y-TZP: 24 Other oxides: 2
t2.6					
t2.7					
t2.8	Density	g/cm <sup>3</sup>	3.97	6.08	4.37
t2.9	Average grain size	µm	1.75	<0.5	0.56 (Al <sub>2</sub> O <sub>3</sub> ) 0.15 (Y-TZP)
t2.10					
t2.11	Bending strength	MPa	630	>1500	1390
t2.12	Fracture toughness	MPa m <sup>1/2</sup>	3.2	9	6.5
t2.13	Elastic modulus	GPa	407	200	358
t2.14	Hardness	HV	1975	1200	1760

457 Notwithstanding the improvements introduced  
458 in the processing of alumina ceramics for clinical  
459 applications, the weak point of this alumina  
460 remains its low toughness that limits the flex-  
461 ibility in design of alumina components. For this  
462 reason, alumina components today are used in  
463 about 15–20 % only of the ceramic implants, the  
464 balance being alumina-zirconia composites (see  
465 section on “[Alumina-Zirconia Composites](#)”).

### 466 Zirconia

467 Zirconia (zirconium dioxide – ZrO<sub>2</sub>) ceramics  
468 were developed and introduced in clinical use  
469 in the late 80s to overcome the toughness limita-  
470 tion of alumina. The early developments were  
471 oriented towards Magnesia-Partially Stabilised  
472 Zirconia (Mg-PSZ), in which the tetragonal  
473 phase is present within large cubic grains  
474 (Ø40 ÷ 50 µm) forming the matrix, a coarse struc-  
475 ture that may negatively influence the wear prop-  
476 erties of joints. Most of the developments were  
477 focused on Ytria stabilised Tetragonal Zirconia  
478 Polycrystal (YTZP), a ceramic constituted by  
479 tetragonal grains some hundreds of nanometer in  
480 size which has been a standard bearing material  
481 in orthopaedics up to the year 2000. The struc-  
482 tural applications of zirconia ceramics are based  
483 on the constrained tetragonal-to-monoclinic  
484 (t-m) phase transformation, which acts as a dissi-  
485 pative mechanism for fracture energy. Briefly, the  
486 phase transformation is associated to the expan-  
487 sion of zirconia lattice (4 vol% in free grains)  
488 and to its change in shape of the crystal cells that

489 have to overcome the constraint of the matrix  
490 grains. The process takes place at the expenses of  
491 the elastic energy field (tensile) associated to the  
492 developing crack, that to advance has in addition  
493 to win the compressive stress field due to grain  
494 t-m transformation. At a macroscopic level, this  
495 results in a toughened ceramic material, having  
496 bending strength twice the one of alumina (900–  
497 1100 MPa Vs. 500–600 MPa).

498 The t-m phase transformation that gives to  
499 zirconia its interesting behaviour is also its main  
500 drawback: zirconia is a metastable material, and  
501 its clinical outcomes were contradictory [23].  
502 The worldwide recall of the zirconia Prozyr®  
503 ball heads made by Saint Gobain Advanced  
504 Ceramics Desmarquest (Evreux, France) led to  
505 the practical abandon of zirconia in arthroplasty,  
506 where thus far it is still used in some niche prod-  
507 ucts only. On the other hand, zirconia has found  
508 recently a wide field of application as a bioma-  
509 terial in dentistry, for the construction of dental  
510 implants, and of the structure of crowns, bridges,  
511 dentures by CAD-CAM processing of presinter-  
512 ed blanks [21].

513 Zirconia is also used as a coating obtained  
514 by in-situ oxidation of zirconium-2,5Nb alloy  
515 (Oxinium®, Smith & Nephew, London, UK).  
516 In spite of many claims of good wear proper-  
517 ties following total knee replacement either total  
518 hip replacement with OxZr femoral component,  
519 doubts have been recently raised about this tech-  
520 nology in terms of wear reduction both in terms  
521 cost/benefits gains. Namely, due to its thickness

522 (5  $\mu\text{m}$ ) the surface zirconia scale can be easily  
523 scratched by third bodies, leading to the increased  
524 wear of the polyethylene counterface [24].

### 525 Alumina-Zirconia Composites

526 The abandon of zirconia opened a technological  
527 gap in arthroplasty. Then, manufacturers focused  
528 their attention of alumina zirconia composites,  
529 especially on two classes of materials called  
530 Zirconia-Toughened Alumina (ZTA) when alu-  
531 mina is the main component and zirconia the bal-  
532 ance, either Alumina-Toughened Zirconia (ATZ)  
533 when the main component is zirconia.

534 The first material of this class used in clinics is  
535 BIOLOX $\Delta$  (Ceramtec GmbH, Plochingen,  
536 Germany), which is formed by a matrix of chro-  
537 mia-doped alumina containing 17 vol% Y-TZP  
538 and 1 vol% of strontium zirconate platelets. For  
539 its peculiar microstructure, this material do not  
540 belong to any of the formerly described classes,  
541 and was identified as AMC: Alumina Matrix  
542 Composite. The finely and homogenous distribu-  
543 tion of Y-TZP both of the platelets is obtained by  
544 nucleation within the alumina matrix during the  
545 sintering cycle.

546 The high bending strength and toughness of  
547 BIOLOX $\Delta$  in comparison with alumina  
548 and Y-TZP is due to the constrained t-m trans-  
549 formation of the zirconia grains: the transforma-  
550 tion imply the compressive deformation of the  
551 alumina matrix that has an elastic modulus (e.g.  
552 stiffness) twice the Y-TZP one (407 GPa Vs.  
553 200 GPa). This increase the energy dissipated in  
554 the phase transformation. In addition, the plate-  
555 lets in BIOLOX $\Delta$  having width/length ratio  
556 1:10 perform as a fibres reinforcing the material  
557 contributing to increase the material toughness.  
558 By December 2014 more than four million ball  
559 heads, inserts and condyles for knee replace-  
560 ments made out BIOLOX $\Delta$  have been sold  
561 worldwide, making this composite the standard  
562 "ceramic" in arthroplasty.

### 563 Nitride Ceramics

564 While titanium nitride (TiN) is clinical since a  
565 long while as a protective coating on metallic

component of joint replacement bearings, bulk 566  
silicon nitride ( $\text{Si}_3\text{N}_4$ ) has been tested for use in 567  
THR cups coupled to metallic either ceramic ball 568  
heads, but the future of this ceramic in arthro- 569  
plasty remains still unclear [25]. 570

### 571 Complications with Ceramic Bearings

572 Due to the improvements introduced in manufac- 572  
turing, fractures of ceramic composites is today 573  
a very rare event. Arthroprostheses Registry data 574  
show that revision for fracture of ceramic compo- 575  
nent occurs with a frequency lower that the one 576  
of stem/neck fractures, either of collapse of the 577  
polyethylene inlays [26]. Fractures are typically 578  
associated to severe trauma either to technical 579  
errors in handling the ceramic components. Insert 580  
fractures are especially due to intraoperative mis- 581  
positioning while the orientation of the cup is 582  
the reason of edge loading of the bearing compo- 583  
nents. Recently much attention was devoted 584  
to noises from THR bearings. Spectrum analysis 585  
demonstrated that the acoustical vibrations are 586  
depending on specific features of the implants. 587  
This explains also the prevalence of the prob- 588  
lem in some Countries and its absence in others, 589  
likely due to the distribution of the devices [27]. 590

### 591 Calcium Phosphate Ceramics

592 Calcium phosphate ceramics (CPCs) are since a 592  
long time used to give bone-bonding behaviour 593  
to the surfaces of metallic joint replacements 594  
(e.g. on THR stems) to enhance bony fixation. 595  
CPC osteoconductive coatings are a well estab- 596  
lished technology in joint replacements and long 597  
term follow-ups confirm the results obtained 598  
in early works [28]. CPC are a family of com- 599  
pound with different in vivo behaviour depend- 600  
ing on a number of parameters especially on 601  
Ca/P ratio the most stable being Hydroxyapatite 602  
 $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$  [29]. 603

604 Osteoconductive CP coatings are made by 604  
plasma spray. A critical aspect in this technol- 605  
ogy is the Ca/P ratio of the starting powder and 606  
its crystallinity. Powder experience a severe 607

608 heating/cooling thermal cycle during this pro- 653  
609 cess. Formation of amorphous phases and of 654  
610 resorbable calcium phosphate ceramic (CPC) 655  
611 compounds, segregation of CaO and oxidation 656  
612 reactions must be carefully controlled. Namely, 657  
613 the rate of bone formation and the resorption 658  
614 of coating and its mechanical stability (shear 659  
615 strength, bond strength, fatigue life) are depend- 660  
616 ing on a number of parameters, like e.g. pres- 661  
617 ence of leachable phases, crystallinity, residual 662  
618 porosity [30]. 663

## 619 **Metallic Materials for Joint** 620 **Prosthesis**

621 Metallic materials with industrial relevance for 670  
622 joint prostheses belong to three main groups 671  
623 [31–36]: (i) stainless steel; (ii) alloys based on 672  
624 the Co-Cr system; (iii) Ti and its alloys. (i) The 673  
625 austenitic AISI 316 stainless steel was the first 674  
626 material used for orthopaedic implants. When it 675  
627 is specified as AISI 316 L, the carbon content is 676  
628 limited to 0.03 wt% for improving the corrosion 677  
629 resistance of this material. (ii) Co-Cr based alloys 678  
630 have been used for total joint prostheses since the 679  
631 early 1900s and are originating from modifica- 680  
632 tions of dentistry alloy Vitallium (Haynes Stellite 681  
633 alloy N. 21). They combine good mechanical 682  
634 properties with a high biocompatibility, due to 683  
635 the presence of Cr, which forms spontaneously 684  
636 a protective oxide layer. The carbon content in 685  
637 the alloy must be carefully controlled, because 686  
638 the formation of carbide phases may be detri- 687  
639 mental for mechanical properties. (iii) Ti and 688  
640 Ti-based alloys are widely used as biomaterials 689  
641 for their high biocompatibility, mainly due to a 690  
642 high corrosion resistance related to the forma- 691  
643 tion of a passive oxide layer at the surface. Good 692  
644 mechanical properties and low density constitute 693  
645 an additional benefit for joint prostheses produc- 694  
646 tion. Commercially pure (cP) Ti is used in differ- 695  
647 ent grades, as a function of the oxygen content 696  
648 as impurity. Common Ti-based alloys contain 697  
649 aluminium (Al) and vanadium (V), the last often 698  
650 substituted by Niobium (Nb) in order to increase 699  
651 biocompatibility. The main components and 700  
652 physical properties of most widely used metallic

biomaterials for joint prosthesis are collected in 653  
Table 5.3. 654

The industrial production of metallic compo- 655  
nents for joint prosthesis may be carried out 656  
in different steps. As a first step, raw metals and 657  
alloys are processed into stock shapes, such as 658  
bars, sheet, rods, plates, tubes, wires and pow- 659  
ders. The second processing step is used to tai- 660  
lor the microstructure of the alloy, which is 661  
strongly related to the mechanical properties of 662  
the implant, by means of thermo-mechanical 663  
treatments. The transformation of stock materi- 664  
als into final products may be obtained by invest- 665  
ment casting, machining, forging, and sintering. 666  
Techniques used to manufacture various alloys to 667  
produce metallic biomaterials for joint prostheses 668  
are collected in Table 5.4. Surface coatings aimed 669  
to improve functional properties of implant (i.e. 670  
biocompatibility, bone fixation) are often added 671  
as a final step. Functionality and duration of 672  
implants in a physiological environment are 673  
very sensitive to surface properties, which may 674  
be considered the most important and selective 675  
aspect for joint prosthesis selection. Surface 676  
treatments are mainly aimed to increase hard- 677  
ness and strength of the surface layer, in order 678  
to improve the resistance to wear and corrosion. 679

Even if metallic biomaterials show good static 680  
mechanical properties, they may suffer signifi- 681  
cantly for fatigue failures [37]. Fatigue strength 682  
is defined as the highest periodic stress that does 683  
not initiate a failure of the material after a given 684  
number of cycles. For hip prostheses, an average 685  
of  $2 \cdot 10^6$  stress cycles per year can be estimated, 686  
so that more than  $10^8$  cycles may be applied dur- 687  
ing a lifetime. The applied stress for fatigue fail- 688  
ures is in the elastic region of the static loading, 689  
so that fatigue strength is significantly lower than 690  
ultimate tensile strength. Metallic biomaterials 691  
have fatigue strengths in air generally well above 692  
the minimum required for joint prosthesis appli- 693  
cations. Mechanical properties of most widely 694  
used metallic biomaterials for joint prostheses 695  
are collected in Table 5.3, together with those of 696  
cortical bones for comparison. 697

Total joint replacements are subjected to 698  
wear and abrasion so that the resistance against 699  
them is an important criterion for biomaterials. 700

**Table 5.3** Typical composition (maximum amount allowed, wt%), physical and mechanical properties of metallic biomaterials

Materials	Main comp.	Other comp. (max wt%)	Density (g cm <sup>-3</sup> )	Yield strength (MPa)	Ultimate tensile strength (MPa)	Fatigue strength (10 <sup>7</sup> cycles) MPa	Fracture toughness (MPa m <sup>1/2</sup> )	Elastic modulus (GPa)	Elongation at fracture (%)
Stainless steels AISI 316	Fe	Ni (14), Cr (19), Mo (2.5), Mn (2)	7.5–8.0	170–790	480–1000	180–550	75–85	190–200	10–50
Co-Cr based alloys	Co	Cr (30), Ni (37), Mo (10.5), Mn (2)	8.2–9.1	250–1500	650–1800	300–950	50–60	210–240	8–50
cP-Ti	Ti	Fe (0.5), O (0.4)	4.5	170–485	240–550	200–330	65–75	110	15–25
Ti based alloys	Ti	Al (6.5), V (4.5), Nb (7.5), Fe (3), Mo (15), Zr (6)	4.4–5.3	800–1050	900–1100	450–650	50–55	75–115	8–20
Cortical bone					80–150	30	2–12	14–22	0–2

t3.1  
t3.2  
t3.3  
t3.4  
t3.5  
t3.6  
t3.7  
t3.8  
t3.9  
t3.10  
t3.11  
t3.12  
t3.13  
t3.14  
t3.15  
t3.16  
t3.17  
t3.18

t4.1 **Table 5.4** Techniques used to produce metallic biomaterials for total joint replacements

t4.2	Technique	Stainless steels	Co-Cr based alloys	cP-Ti	Ti based alloys
t4.3	Casting	Not used	Investment casting	Difficult	Difficult
t4.4	Machining	Possible	Difficult	Possible	Possible
t4.5	Cold working	Rolling	Difficult	Rolling	Difficult
t4.6	Hot working	Wrought, forged	Wrought, forged	Not used	Wrought, forged
t4.7	Sintering	Possible	Hot isostatic pressing	Not used	Not used
t4.8	Thermal treatments	Recrystallisation	Precipitation hardening	Recrystallisation	Precipitation hardening

701 High carbon Co-Cr based alloys (F75) improve  
 702 significantly mechanical properties after work-  
 703 ing, so that small plastic deformations at the  
 704 surface significantly increase the hardness of the  
 705 alloy and, as a consequence, its wear resistance.  
 706 In addition, the presence of fine dispersed hard  
 707 carbides increases the wear resistance of these  
 708 alloys. Oxide films formed by passivation at  
 709 the surface of the Cr and Ti containing alloys  
 710 are generally resistant to abrasion [38]. Load  
 711 required to fracture the oxide surface film is  
 712 lower for Ti-based alloys with respect to Co-Cr  
 713 based alloy.

714 In conclusion, the ideal alloy should have the  
 715 elastic modulus of bone, the strength of cobalt-  
 716 chromium alloys, the corrosion resistance and  
 717 biocompatibility of titanium alloys, and the fab-  
 718 rication cost of stainless steels [35, 36]. Each  
 719 material has advantages and disadvantages,  
 720 which drive applications. Stainless steels have  
 721 good corrosion and fatigue resistance in short-  
 722 term applications, have a low cost and they are  
 723 easy to be machined, but tend to be corroded in  
 724 long-term applications, have a high elastic mod-  
 725 ulus and can produce Ni and Cr allergy. Co-Cr  
 726 based alloys show long-term corrosion resis-  
 727 tance, a high fatigue and wear resistance and a  
 728 good biocompatibility, but they are difficult to  
 729 machine, and thus expensive to process, and, like  
 730 stainless steel, they suffer for a high elastic mod-  
 731 ulus and Ni and Cr allergy. Ti-based alloys have  
 732 a low density, joined with a relatively low elastic  
 733 modulus, show the greatest corrosion resistance  
 734 and have an excellent biocompatibility, but they  
 735 have a relatively low shear strength and wear  
 736 resistance and are quite expensive. As far as con-  
 737 cern the total hip replacement, Table 5.5 reports  
 738 the types of bearing types implanted in Italy on  
 739 2014 [39].

**Table 5.5** Types of total hip replacement bearings implanted in Italy on 2014

Bearing type			15.3
Head	Cup	Share (%)	15.4
Ceramic	Polyethylene	50.7	15.5
Ceramic	Ceramic	28.5	15.6
Metal	Polyethylene	16.7	15.7
Metal	Metal	2.8	15.8
Ceramic	Metal	0.7	15.9
Metal	Ceramic	0.5	15.10
Other		0.2	15.11

Data from Torre et al. [39] 15.12

**References**

740

1. Williams DF. Definition in biomaterials. Proceedings of the consensus conference of the European Society for Biomaterials, Chester, 1986. Amsterdam: Elsevier Ed.; 1987. p. 49–59. 741-744
2. Mertz L. What is biocompatibility? A new definition based on the latest technology. IEEE Pulse. 2013;4:14–5. 745-747
3. Holzapfel BM, Reichert JC, Schantz JT, Gbureck U, Rackwitz L, Nöth U, Jakob F, Rudert M, Groll J, Hutmacher DW. How smart do biomaterials need to be? A translational science and clinical point of view. Adv Drug Deliv Rev. 2013;65:581–603. 748-752
4. Yao Z, Keeney M, Lin TH, Pajarinen J, Barcay K, Waters H, Egashira K, Yang F, Goodman S. Mutant monocyte chemoattractant protein 1 protein attenuates migration of and inflammatory cytokine release by macrophages exposed to orthopedic implant wear particles. J Biomed Mater Res A. 2014;102:3291–7. 753-759
5. Visuri T, Pulkkinen P, Paavolainen P, Pukkala E. Cancer risk is not increased after conventional hip arthroplasty. Acta Orthop. 2010;81(1):77–81. 760-762
6. Visuri T, Borg H, Pulkkinen P, Paavolainen P, Pukkala E. A retrospective comparative study of mortality and causes of death among patients with metal-on-metal and metal-on-polyethylene total hip prostheses in primary osteoarthritis after a long-term follow-up. BMC Musculoskelet Disord. 2010; 11:78. 763-769

- 770 7. Doherty AT, Howell RT, Bisbinas I, Learmonth ID, 829  
771 Newson R, Case CP. Increased chromosome translo- 830  
772 cations and aneuploidy in peripheral blood lympho- 831  
773 cytes of patients having revision arthroplasty of the 832  
774 hip. *J Bone Joint Surg Br.* 2001;83B(7):1075–81. 833  
775 8. Granchi D, Cenni E, Giunti A, Baldini N. Metal 834  
776 hypersensitivity testing in patients undergoing joint 835  
777 replacement: a systematic review. *J Bone Joint Surg 836*  
778 *Br.* 2012;94(8):1126–34. 837  
[AU719] 9. Kurtz S. In: Kurtz S, editor. UHMWPE biomaterials 838  
780 handbook. 3rd ed. New York: Academic; 2015. In 839  
781 press. 840  
[AU782] 10. [www.UHMWPE.uni...](http://www.UHMWPE.uni...) 841  
783 11. Brach del Prever EM, Bistolfi A, Bracco P, Costa 842  
784 L. UHMWPE for arthroplasty: past or future? 843  
785 *J Orthop Traumatol.* 2009;10:1–8. 844  
786 12. Bracco P, Brach del Prever E, Cannas M, et al. 845  
787 Oxidation behaviour in prosthetic UHMWPE compo- 846  
788 nents sterilised with high energy radiation in a 847  
789 low oxygen environment. *Polym Degrad Stab.* 848  
790 2006;91:2030–8. 849  
791 13. Costa L, Bracco P, Brach del Prever E, et al. A survey 850  
792 of oxidation and oxidation potential in contemporary 851  
793 packaging for polyethylene total joint replacement 852  
794 components. *J Biomed Mater Res.* 2006;78B(1): 853  
795 20–6. 854  
796 14. Costa L, Bracco P, Brach del Prever E, et al. Analysis 855  
797 of products diffused into UHMWPE prosthetic com- 856  
798 ponents in vivo. *Biomaterials.* 2001;22(4):307–15. 857  
799 Costa L, Bracco P. Chapter 27: Mechanism of cross- 858  
800 linking and oxidative degradation and antioxidant 859  
801 stabilization of UHMWPE. In: Kurtz S, editor. 860  
802 UHMWPE biomaterials handbook. 3rd ed. New York: 861  
803 Academic; 2015. In press. 862  
804 16. Wolf C, Lederer K, Bergmeister H, Losert U, Böck 863  
805 P. Animal experiments with ultra-high molecu- 864  
806 lar weight polyethylene (UHMW-PE) stabilised 865  
807 with  $\alpha$ -tocopherol used for articulating surfaces 866  
808 in joint endoprostheses. *J Mater Sci Mater Med.* 867  
809 2006;17(12):1341–7. 868  
810 Kurtz S, Bracco P, Costa L. Chapter 17: Vitamin 869  
811 E-Blended UHMWPE Biomaterials. In: Kurtz S, 870  
812 editor. UHMWPE biomaterials handbook. 3rd ed. 871  
813 New York: Academic; 2015. 872  
814 18. Wixon RL, Lautenschlager EP. Methyl methacrylate. 873  
815 In: Callagan JJ, Rosenberg AG, Rubash HE, editors. 874  
816 The adult hip. Philadelphia: Lippincott-Raven Pub.; 875  
817 1998. p. 187–200. 876  
818 19. Brach del Prever EM, Costa L, Baricco M, Piconi C, 877  
819 Massé A. Biomaterials for joint prosthesis. In: EFORT 878  
820 (European Federation of National Associations of 879  
821 Orthopaedics and Traumatology), editor. Surgical 880  
822 techniques in orthopaedics and traumatology. Paris: 881  
823 Elsevier; 2004. 882  
824 20. Trippel SB. Antibiotic-impregnated cement in 883  
825 total joint arthroplasty. *J Bone Joint Surg (A).* 884  
826 1986;68A:1297–302. 885  
827 21. Piconi C, Condò SG, Kosmac T. Alumina- and zirco- 886  
828 nia-based ceramics for load bearing applications. In: 887  
Shen JZ, Kosmac T, editors. *Advanced ceramics for* 829  
*dentistry.* 1st ed. Waltham: Butterworth-Heinemann; 830  
2014. p. 220–53. 831  
22. Piconi C. Alumina. In: Ducheyne P, Healey KE, 832  
Hutmacher DW, Grainger DW, Kirkpatrick CJ, edi- 833  
tors. *Comprehensive biomaterials*, vol. 1. 1st ed. 834  
Amsterdam: Elsevier; 2011. p. 73–94. 835  
23. Piconi C, Maccauro G, Angeloni M, Rossi B, 836  
Learmonth ID. Zirconia heads in perspective: a survey 837  
of zirconia outcomes in total hip replacement. *Hip Int.* 838  
2007;17:119–30. 839  
24. Piconi C, Porporati AA, Streicher RM. Ceramics in 840  
THR bearings: behavior in off-normal conditions. 841  
*Key Eng Mater.* 2015;631:1–7. 842  
25. Piconi C. Non-oxide ceramics. Status quo in THR and 843  
future options. In: Cobb JP, editor. *Modern trends in* 844  
*THA bearings.* Berlin: Springer; 2010. p. 37–44. 845  
26. Sadoghi P, Pawelka W, Liebensteiner MC, Williams 846  
A, Leithner A, Labek G. The incidence of implant 847  
fractures after total hip arthroplasty. *Int Orthop.* 848  
2014;38:39–46. 849  
27. Owen DH, Russell NC, Smith PN, Walter WL. An 850  
estimation of the incidence of squeaking and revi- 851  
sion surgery for squeaking in ceramic-on-ceramic hip 852  
replacement. *Bone Joint J.* 2014;96-B:181–7. 853  
28. Geesink RGT. Osteoconductive coatings for total 854  
joint arthroplasty. *Clin Ortop.* 2002;395:53–65. 855  
29. Rey C, Combès C, Drouet C, Grossin D. Bioactive 856  
ceramics: physical chemistry. In: Ducheyne P, Healey 857  
KE, Hutmacher DW, Grainger DW, Kirkpatrick CJ, 858  
editors. *Comprehensive biomaterials*, vol. 1. 1st ed. 859  
Amsterdam: Elsevier; 2011. p. 187–221. 860  
30. Sun L, Berndt C, Gross KA, Kukuc A. Material 861  
fundamentals and clinical performances of Plasma 862  
spray coatings: a review. *J Biomed Mater Res (Appl 863*  
*Biomater).* 2001;58:570–92. 864  
31. Helsen JA, Breme HJ, editors. *Metals as biomaterials.* 865  
Chichester: Wiley; 1998. 866  
32. Brunski JB. Metals. In: *Biomaterials science*, vol. 2. 867  
Academic Press; 1996. p. 37. 868  
33. Gilbert JL. Metals. In: Callaghan JJ, Rosenberg AG, 869  
Rubash HE, editors. *The adult hip*, vol. 8. Philadelphia: 870  
Lippincott-Raven Publishers; 1998. p. 134. 871  
34. Ashby MF. *Materials selection in mechanical design.* 872  
Oxford: Butterworth-Heinemann; 1999. 873  
35. Chen Q, Thouas AG. Metallic implant biomaterials. 874  
*Mater Sci Eng R.* 2015;87:1–57. 875  
36. Davies JR, editor. *Metallic materials.* In: *Handbook of* 876  
*materials for medical devices.* Materials Park: ASM 877  
International; 2003. p. 21–50. 878  
37. Teoh SH. Fatigue of biomaterials: a review. *Int 879*  
*J Fatigue.* 2000;22:825–37. 880  
38. Bolton J, Hu X. In vitro corrosion testing of PVD 881  
coatings applied to a surgical grade Co-Cr-Mo alloy. 882  
*J Mater Sci Mater Med.* 2002;13:567–74. 883  
39. Torre M, Luzi I, Carrani E, Leone L, Romanini 884  
E, Zanolì G. RIAP, Progetto Registro Italiano 885  
Artroprotesi – idea, sviluppo, avvio. Roma: Il 886  
Pensiero Scientifico; 2014. p. 144. 887

# Author Queries

Chapter No.: 5      0002666220

<b>Queries</b>	<b>Details Required</b>	<b>Author's Response</b>
AU1	Please update Refs. [9, 15].	
AU2	Please provide title and year for Ref. [10].	
AU3	Please provide publisher location for Ref. [32].	

Uncorrected Proof